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The drug abuse crisis now apparent in the 
U.S. has raised questions about some of our 
oldest and most fundamental assumptions 
regarding the effects of our systems for con- 
trolling the availability of drugs of abuse. 
Indeed, we have been compelled to reconsi- 
der whether we might not be better off with 
out our venerable legal sanctions against 
these substances, especially when the clear- 
est effects of these laws has been to make 
illegal commerce in these drugs so competi- 
tive as to imperil the safety of our streets 
and neighborhoods and so lucrative as to 
corrupt and destabilize the governments of 
whole nations. 
In the case of drugs with abuse liability 
that also have significant medical value, the 
issues of regulatory control, though less 
dramatic, may be even more difficult: Here 
the aim of societal controls is not only to 
restrict the availability of these substances 
for abuse, but to do so without restricting 
their appropriate medical use. However, we 
generally assume that the regulations by 
which we choose to safeguard society will 
have the intended effects; and we assume no 
less of the regulations we apply to therapeu- 
tic drugs. This assumption has by and large 
gone unexamined and untested. 
In fact, considering the history of these 
regulations on both the national and interna- 
tional levels, it is not clear that they have 
reduced the abuse of these drugs more than 
their appropriate use. Indeed, it is a telling 
commentary on the current state of affairs 
that one can question whether such regula- 
tions have had any effect on abuse of these 
drugs at all [1,2]. On the other hand, there is 
some evidence that societal controls have led 
to serious restrictions in the therapeutic use 
of some drugs, and thus to unnecessary suf- 
fering. 
Perhaps the best case in point is that of 
narcotic analgesics, which first came under 
control in the U.S. in 1914 because of their 
“addictive” properties. It was noted as early 
as 1918 that these controls deterred medical 
use of these drugs [3]. More recent studies 
have consistently found that physicians man- 
aging pain tend to underuse these medica- 
tions, apparently because of fears of inducing 
dependence - so that a substantial propor- 
tion or even the majority of hospital patients 
requiring analgesia continue to suffer moder- 
ate to excruciating pain [4 -81. What is the 
purpose of this suffering, when the actual 
risk of ‘addiction’ among such patients is 
very slight - possibly less than 0.01% [9,10]. 
We must reassert the need to practice 
medicine on the basis of science, rather than 
to be governed by societal pressures inspired 
by fears of ‘addiction’. The challenge to 
research is to provide a clearer view of the 
phenomena of physiological and psychological 
dependence and of their social and clinical 
significance; and to better qualify the mean- 
ing of drugs’ abuse liability in terms of the 
relative risks they pose for patients and for 
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others. An overlapping objective is to begin 
to test the assumptions underlying regulation 
of therapeutic drugs with abuse liability, and 
to elucidate ways in which these regulations 
or their implementation may be improved. 
There are a great many research needs in 
this area. The paramount needs are to 
develop sensitive and reliable measures of 
the consequences of drug regulation; and to 
increase the frequency, regularity, and scope 
of efforts to examine these effects. The goal 
is to establish ongoing monitoring systems 
that can provide an accumulation of experi- 
ence to guide future policy-making. 
An illustrative case: regulation of benzodi- 
azepines 
It is instructive to consider these issues in 
the context of public policy governing the 
use of the benzodiazepines. These drugs have 
long been established as effective in therapy 
for anxiety and insomnia and are the agents 
most commonly used in treating these disor- 
ders; because of their role in treatment of 
musculoskeletal and convulsive disorders, 
they are classified as ‘essential’ drugs by the 
World Health Organization. The sheer vol- 
ume of information available from research 
on the use and abuse of this group of drugs 
is probably greater than that for any other 
drug class. It is interesting to inquire how 
well this body of information has served, and 
how it might serve better, as a basis for 
regulation of these compounds. 
Information relevant to regulation 
numerous studies of prescribing behavior 
and of actual drug use in the community indi- 
cate that the vast majority of use of 
benzodiazepines is appropriate with respect 
to the patients and conditions treated [ll]. 
Epidemiologic research has also indicated 
that, at least in the U.S., the majority of 
people suffering high levels of psychic dis- 
tress [12], or diagnosable anxiety syndromes 
[13], go without anxiolytic treatment. Thus 
the risk here is one of undertreatment [14]; it 
follows that particular caution is needed to 
avoid further restricting appropriate treat- 
ment for these problems. 
What risks do the benzodiazepines pose? 
They are clearly safer in overdose than older 
sedatives/hypnotics, e.g. the barbiturates [15]. 
With regard to abuse, I will briefly summa- 
rize the findings of a recent review [ll]: 
Although experimental models cannot be 
regarded as definitive predictors of abuse 
liability, the findings of experimental assess- 
ments of benzodiazepines’ abuse liability 
have found remarkable parallels in epidemiol- 
ogic research. That is, laboratory studies 
have demonstrated little or no reinforcing 
effects of benzodiazepines in normal subjects 
nor in subjects representative of typical 
patient populations; however, some 
preference for benzodiazepines has been 
demonstrated among subjects with histories 
of sedative abuse. Similarly, drug abuse sur- 
veys find little or no misuse or recreational 
use of benzodiazepines among the general 
population, but a greater prevalence of use 
of these drugs in various populations of abu- 
sers, including patients on methadone 
maintenance, opioid abusers, and, perhaps, 
alcoholics. Thus, abuse of benzodiazepines is 
limited to the relatively small population of 
individuals who tend to abuse multiple drugs. 
Clinical studies have shown that physiological 
dependence can develop in patients taking 
therapeutic doses of benzodiazepines over 
prolonged periods; however, this dependence 
does not appear to be accompanied by escala- 
tion of dose or drug-seeking behavior, which 
would characterize abuse. 
Current regulution at the national and Gzter- 
national levels 
The principal effect of international con- 
trol of the benzodiazepines, under Schedule 
IV of the Psychotropic Convention of the 
U.N., is that these drugs may be dispensed 
only upon medical prescription. In the U.S., 
benzodiazepines are also controlled under 
Schedule IV of the Controlled Substances 
Act, so that prescriptions can be refilled no 
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more than five times within six months of 
the original prescription. 
Regulation by New York State 
However, consider the instance of a regu- 
lation imposed in January 1989, by New York 
State. Under this regulation, benzodiazepine 
prescriptions can now be issued only on the 
State’s official triplicate prescription forms, of 
which one copy must be submitted to the 
Department of Health for purposes of 
computerized surveillance. For the most preva- 
lent disorders for which these drugs are used, 
prescriptions are limited to a 30-day supply and 
cannot be refilled. This multiple-copy prescrip- 
tion program had previously been applied, in 
New York and other states, primarily to drugs 
listed in Schedule II of the federal Controlled 
Substances Act, i.e., drugs whose abuse can 
lead to ‘severe psychological or physical depen- 
dence’ (21 U.S.C. 812(b12Gll. The ostensible 
reason for adopting this regulation was to 
reduce illicit traffic in and abuse of benzodiaze- 
pines. However, the evidence of abuse 
presented by the State was not compelling. For 
example, the State’s argument [16] rested heav- 
ily on data from the Drug Abuse Warning Net- 
work (DAWN) pertaining to emergency room 
visits in which benzodiazepines were involved; 
in fact, an official analysis of DAWN data for 
1976 - 1985 found that such visits significantly 
declined over this period, both for the U.S. as a 
whole and specifically for the New York State 
facilities reporting to the system [17]. Conspieu- 
ously absent from the State’s argument was 
,any attempt to describe how or whether this 
alleged abuse might relate to legitimate use of 
these drugs, as well as any attempt to indicate 
exactly how this specific regulatory action was 
supposed to reduce the types of abuse and 
other problems described. 
The implicit assumption about prevalence of 
use 
The underlying motivation for this regula- 
tion may have been revealed by the empha- 
sis, in the State’s argument [Iti], on the 
‘enormous’ prevalence of use of the benzodi- 
azepines. The implicit assumption was that 
this widespread use alone must be evidence 
of some problem, e.g., overprescription or 
abuse. If the prevalence of drug use alone 
should raise suspicions, why did New York 
choose to act against the benzodiazepines 
rather than, say, beta blockers or antiinflam- 
matory agents, which are even more widely 
used? 
Conspicuously absent from this part of the 
State’s argument was any attempt to relate 
the prevalence of use of these drugs to the 
prevalence of the health problems for which 
their use is indicated. As I have argued pre- 
viously [ll], the prevalence of use of seda- 
tive/hypnotic medications has not changed 
appreciably over the period since the time of 
the earliest relevant records - i.e., for at 
least the better part of a century. It seems 
reasonable to assume that the need for such 
drugs is related to the prevalence of the ill- 
nesses for which they are used, which affect 
about 15 to 20% of virtually any population 
studied. 
In states where multiple-copy prescription 
programs have been implemented, prescrip- 
tions for the affected drugs have declined by 
30 to 55O/0 in the programs’ first two years 
[18]. Based on this experience, as well as the 
thrust of the New York State argument, it 
seems clear that the State intended not 
merely to curtail abuse of benzodiazepines 
but to reduce the overall prevalence of their 
use. Predictably, then, prescription audit 
data from New York State indicate that ben- 
zodiazepine prescriptions have already 
declined by about 50% [19]. Since, as 
described above, the best available informa- 
tion indicates that the vast majority of ben- 
zodiazepine prescriptions are appropriate, 
and that abuse is virtually limited to the 
relatively small population of multiple-drug 
abusers, the New York State regulation is 
clearly affecting medical use more than abuse 
of these drugs. 
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Lessons about the role of research 
If drug regulations are to safeguard the 
public health, what safeguards do we have 
against drug regulations that are expressions 
of prejudice rather than science? The dis- 
tressingly inappropriate regulation imposed 
by New York State emphasizes the impor- 
tance of building meaningful scientific 
accountability into the regulatory structure. 
The legislation under which the New York 
State Commissioner of Health acted gave 
him the power to impose this regulation with 
no obligation to assess the relevant scientific 
evidence nor to defend the merits of his deci- 
sion on the basis of such evidence. This kind 
of drug legislation, providing no effective 
role for the findings of good research in the 
policy-making process, can lead to a form of 
authoritarian control that is not only incon- 
sistent with good public health practice but 
which, as in this case, can actually jeopardize 
the public health. 
Fortunately, many regulatory systems, 
particularly at the national and international 
levels, do at least require expert assessments 
of the available evidence as based for policy 
decisions. Even these systems are flawed, 
however, in that they do not mandate nor 
provide mechanisms for surveillance of the 
actual impact of drug regulation on abuse 
and on medical use of the drugs affected; 
without such surveillance there is no assur- 
ance that these regulations actually operate 
in the best interests of the public health. 
Another important lesson from the New 
York State experience is that, with respect 
to therapeutic drugs, it is inappropriate to 
draw policy conclusions based on evidence of 
abuse alone. Such evidence rarely includes 
adequate characterization of the circum- 
stances or patterns of abuse, or, most impor- 
tantly, of the population at risk. As 
illustrated by the example of the benzo- 
diazepines, abuse liability is not an intrinsic 
pharmacologic property of a drug or drug 
group, such that it necessarily places all popula- 
tions at equal risk; rather, abuse liability can 
differ not only among individuals but also 
among populations and among environmental 
circumstances. 
Research needs 
Thus it is important to establish the relev- 
ance of evidence of abuse as a basis for regu- 
latory policy. This requires research designed 
to specify the relative risks for different 
population subgroups. The most promising 
approach is epidemiologic research designed 
to examine the variety of ways in which a 
drug available to a population is actually 
used, i.e., examination of both use and abuse 
in the same population. 
For example, studies of the use and abuse 
of benzodiazepines have included computer- 
based drug utilization reviews which focused 
on records of prescriptions dispensed within 
large medical complexes [20 - 221; prospective 
studies of all individuals within a region who 
filled sedative/hypnotic prescriptions, which 
examined these individuals’ subsequent pre- 
scription purchases over time [23-251; and 
community surveys in which respondents 
were asked about medical and nonmedical 
use of various psychotropics [26]. 
It is research of this kind that can provide 
the information necessary to tailor reguia- 
tions to the specific risks that drugs actually 
pose. In addition, the implementation of 
ongoing studies of this kind, i.e., studies that 
examine use and abuse in the same popula- 
tions would enable us to monitor the effects 
of regulatory interventions, and to build a 
cumulative information base for use in formu- 
lation of drug policy. 
In considering policy on drugs with sub- 
stantial medical value and use, we should be 
concerned primarily with the potential 
effects on people who might benefit from 
treatment with these agents. If we are con- 
cerned about the risk of abuse of a given 
drug among these people, we should rely on 
studies of its liability for abuse in these peo- 
ple or their representatives. It is not reason- 
able to deprive a patient of a potentially 
beneficial medication in the interest of reduc- 
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ing the risk that it might be abused by some- 
one else. 
Conclusion 
If it is in the interest of the public health 
to require that drugs meet certain standards 
of safety and efficacy. It should be of equal 
concern that regulations affecting the availa- 
bility of these drugs should prove safe and 
effective. A primary role for research, in 
addition to providing reliable information on 
the abuse liability of therapeutic drugs, 
should be to help establish standards for the 
safety and efficacy of regulatory interven- 
tions. When we apply regulations, we should 
have systems in place for monitoring 
whether they do have their intended effects, 
and for detecting and measuring the frequency 
of their unintended and unwanted effects. 
As scientists, we should regard each 
instance in which a regulation is imposed on 
a therapeutic compound as an opportunity 
for evaluation of the effects of this interven- 
tion: the intended effects on the behavior of 
prescribers, patients, and drug abusers, as 
well as an array of possible secondary 
effects. It is time that we learn to take 
advantage of these natural experiments, 
beginning by establishing appropriate meas- 
ures of these effects. 
As advisors on drug policy, we should 
ensure that these measures are carefully 
constructed and systematically applied, to 
provide an accumulation of experience on 
which to base regulations that will protect 
rather than jeopardize the public health. 
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